The AHEAD-MERIT trial will take place in 15 hospitals, targeting patients with aggressive HPV-associated cancers with an innovative vaccine.
Gabriel Dumitrache
International
Foto: Shutterstock
Always see our news on Google
The AHEAD-MERIT clinical trial will take place in 15 hospitals in England, targeting patients with aggressive human papillomavirus (HPV)-associated cancers. These cancers have high rates of recurrence and poor survival. The vaccine being developed targets proteins commonly found in HPV-associated head and neck cancer. The health secretary declared the initiative a "huge victory" and NHS England is working with BioNTech to identify eligible patients. This is the third trial under the NHS Cancer Vaccine Launch Pad, which has already supported 550 patients.
Sources
Latest News
22:57
Traian Băsescu says that AUR "has reached the end of its growth potential" and will have to explain "the money it gave to television stations"
22:50
Paramount Skydance and Warner Bros Discovery will form Skydance after the completion of a $110 billion deal
22:36
The sixth day of protests at the Central Detention Center: Supporters of Călin Georgescu demand his release
22:14
Traian Băsescu, regarding the government crisis: “They have no solution left except an independent prime minister”
21:56
Britain’s Green Party voted to classify Zionism as racism / Israel accuses the party of legitimizing terrorism
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
